CTRI/2014/05/004579已完成4 期
A randomized, double blind, parallel group, proof of concept study to evaluate the efficacy of ablend of rice bran oil and safflower oil (7:3) with antioxidants in comparison with olive oil inadult hyperlipidemic subjects. - Nil
Spectrum Clinical Research Pvt Ltd0 个研究点目标入组 172 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •LDL levels ( >= 130 mg/dL and < 190mg/dL)
- •hsCRP >1 mg/L
- •Patient with body mass index of >18.5kg/m 2 and < 30 kg/m2
- •Untreated Dyslipidemia
- •Willingness to maintain current activity levels and follow the prescribed diet
排除标准
- •Use of oral or injected corticosteroids or anabolic steroids at Visit 1 or prior to randomization.
- •Poorly controlled hypertension (resting blood pressure >=160 mm Hg and systolic and/or >=100 mm Hg diastolic).
- •Uncontrolled hypothyroidism or thyroid stimulating hormone
- •Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as >14 drinks per week.
- •Current smoker
- •Exposure to any investigational product within 4 weeks prior to Visit 1, or prior to randomization
- •Women who are pregnant, lactating, or planning to become pregnant.
- •Liver disorders.
- •Taking lipid lowering drugs
- •Congestive cardiac failure, acute myocardial infarction within last 1 month.
研究者
相似试验
已完成
4 期
Study to evaluate the efficacy of a blend of rice bran oil and safflower oil in comparison with routinelyconsumed oil in adult hyperlipidemic subjects.CTRI/2013/11/004138Spectrum Clinical Research Pvt Ltd86
已完成
3 期
CLINICAL TRIAL OF IN-AQUL-001 TO TREAT PRIMARY INSOMNIA IN ADULT & ELDERLY PATIENTSCTRI/2010/091/001443Intas Pharmaceuticals Limited280
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy and Safety of Fusidic Acid Hydrophilic Cream 20 mg/g and Fucidin® Cream in the Treatment of Adult and Pediatric Subjects with Impetigo.Impetigo contagiosaMedDRA version: 20.0Level: PTClassification code 10021531Term: ImpetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10041923Term: Staphylococcal impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10042178Term: Streptococcal impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10021535Term: Impetigo NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10041939Term: Staphylococcus aureus impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10042200Term: Streptococcus pyogenes impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10021533Term: Impetigo contagiousSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002219-24-BEBasic Pharma Technologies200
已完成
3 期
Clinical trial on Irritable Bowel Syndrome having constipation.CTRI/2020/05/024972Zeushygia Life Sciences Pvt Ltd
进行中（未招募）
1 期
AN EQUIVALENCE TRIAL TO COMPARE THE EFFICACY, SAFETY, PHARMACOKINETICS AND IMMUNOGENICITY OF HD204 TO AVASTIN® IN PATIENTS WITH LUNG CANCER.on-squamous Non-small Cell Lung Cancer (nsNSCLC)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 100000004864EUCTR2017-005175-78-LVPrestige BioPharma Limited592